Boehringer Ingelheim BI 3034701 First-in-Class GLP-1/GIP/NPY2 Triple Receptor Agonist Continues Phase 2 Enrollment in Obesity
Boehringer Ingelheim continues enrollment through September 2026 in the Phase 2 clinical trial of BI 3034701 (a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist), which the company initiated in July 2026 as part of the expanded obesity pipeline anchored on survodutide (dual GLP-1/glucagon agonist, in Phase 3 MASH with Zealand Pharma partnership). BI 3034701 was discovered via the Boehringer-Gubra Biopharmaceutical peptide discovery collaboration and is designed to engage the NPY2 receptor alongside GLP-1 and GIP receptors — a differentiated triple-target mechanism versus Eli Lilly's retatrutide (GIP/GLP-1/glucagon) and Hengrui's ribupatide (GIP/GLP-1/glucagon). The NPY2 receptor pathway is involved in central appetite regulation and has been targeted historically by hormones including PYY(3-36); Boehringer positions BI 3034701 as engaging appetite regulation through a complementary mechanism to the incretin axis. Phase 2 readout timing has not been publicly disclosed. Boehringer Ingelheim's overall obesity pipeline positions the company as a distant third-place challenger to Eli Lilly and Novo Nordisk with survodutide, BI 3034701, and the emerging GLP-1/glucagon dual agonist program.